GPCR vs MNKD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GPCR · Structure Therapeutics$16.13 ▼ 5.78%
MNKD · MannKind$3.85 ▼ 2.53%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GPCR -54.3%
- MNKD -25.0%
Head to head
| Metric | GPCR | MNKD |
|---|---|---|
| Price | $16.13 | $3.85 |
| Change today | ▼ 5.78% | ▼ 2.53% |
| Market cap | $1.15B | $1.24B |
| Return, 3 months | -67.1% | -5.4% |
| Return, year to date | -76.8% | -32.1% |
| Return, 1 year | -53.0% | -23.5% |
| P/E (TTM) | – | – |
| P/B | 0.9 | -33.2 |
| P/E percentile vs own 5y | 99th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +24.0% |
| Net profit growth (YoY) | -120.3% | -390.8% |
| Gross margin | – | 75.8% |
| Operating margin | – | -3.4% |
| Net margin | – | -18.1% |
| Return on equity | -29.5% | – |
| Analyst target vs. price | +542.7% | +120.8% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 22 | 52 |
| 30-day volatility | 61.9% | 51.9% |
| Max drawdown, 1 year | -82.8% | -63.3% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MNKD is the largest of the group by market value.
- MNKD has returned the most over the past year.
- MNKD has been the calmest stock over the last 30 days.